Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hemmelder, M.
Right arrow Articles by de Jong, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemmelder, M.
Right arrow Articles by de Jong, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 14, Issue 1 98-104, Copyright © 1999 by Oxford University Press


ORIGINAL ARTICLES

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease

M Hemmelder, D de Zeeuw and P de Jong
Groningen Institute for Drug Studies (GIDS), Department of Medicine, Division of Nephrology, and Department of Clinical Pharmacology, University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

Background: Non-dihydropyridine calcium antagonists such as verapamil are equally effective in reducing proteinuria as ACE inhibitors in hypertensive patients with diabetic nephropathy. To date it is unknown whether verapamil elucidates such an antiproteinuric capacity in non-diabetic renal disease. Methods: We performed a double-blind, placebo controlled, random cross-over study which compared the antiproteinuric effect of 6 weeks treatment with verapamil SR (360 mg) to that of the ACE inhibitor trandolapril (4 mg), and their fixed combination vera/tran (180 mg verapamil SR and 2 mg trandolapril) in 11 non-diabetic patients with proteinuria of 6.6 (5.1-8.8) g/day, a creatinine clearance of 87 &74-106) ml/min, and a 24-h blood pressure of 136/85 (126/76-157/96) mmHg at baseline. Results: Twenty-four-hour mean arterial pressure did not change during verapamil, whereas both trandolapril and vera/tran induced a significant reduction in MAP. Verapamil showed no significant effects on renal haemodynamics. Trandolapril and vera/tran did not significantly change GFR, but ERPF increased and FF decreased during both treatments (P<0.05). The antiproteinuric response of verapamil was significantly less compared to that of trandolapril and vera/tran (-12% (-17/-1) vs -51% (-56/-25) and -41% )-50/-19) respectively). The blood pressure and antiproteinuric response during verapamil tended to be greater in hypertensive patients than in normotensive patients, although this difference was not significant. Baseline blood pressure was related to the change in blood pressure during verapamil (r=-0.70; P<0.02). Conclusions: The antiproteinuric and antihypertensive response of verapamil is less than that of the ACE inhibitor trandolapril in patients with non-diabetic renal disease. In contrast to the antiproteinuric response of trandolapril, the antiproteinuric response of verapamil seems to be completely dependent from effective blood pressure reduction. The fixed combination of verapamil and ACE inhibition at half doses has similar effects as ACE inhibition as full dose. Key words: ACE inhibition, non-diabetic renal disease; proteinuria; verapamil
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Gerdemann, Z. Wagner, A. Solf, U. Bahner, A. Heidland, J. Vienken, and R. Schinzel
Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality
Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1045 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, T. Inoue, N. Shimada, and H. Koide
Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis
Nephrol. Dial. Transplant., May 1, 2002; 17(5): 798 - 802.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.